Long Non-Coding RNA TUG1 Modulates Proliferation, Migration, And Invasion Of Acute Myeloid Leukemia Cells Via Regulating miR-370-3p/MAPK1/ERK.

abstract：Purpose:Gastric carcinoma is the second most frequently diagnosed cancer and leading cause of cancer death in China. As a new generation of cancer therapeutic drug, CL-6, a curcumin derivative, shows better bioavailability than curcumin, which has shown anticancer effects in gastric cancer (GC). However, whether CL-6 s...

journal_title：OncoTargets and therapy

authors： Ye C,Wang W,Xia G,Yu C,Yi Y,Hua C,Tu F,Shen L,Chen C,Sun W,Zheng Z

更新日期：2019-03-27 00:00:00

abstract：:Myelodysplastic syndromes (MDS) are a varied group of diseases leading to significant morbidity and mortality. Therapy of MDS has been difficult, with supportive cares used to ameliorate symptoms, and hematopoietic stem cell transplantation the only curative option. Agents, such as the cytidine analog azacitidine, exe...

journal_title：OncoTargets and therapy

authors： McCormack SE,Warlick ED

更新日期：2010-09-07 00:00:00

abstract：AIMS:Metastasis-associated gene 2 (MTA2) is reported to play an important role in tumor progression, but little is known about the role of MTA2 in nasopharyngeal carcinoma (NPC). The aim of the study was to explore the expression and function of MTA2 in NPC. METHODS:Expression of MTA2 in NPC tissues and cell lines was...

journal_title：OncoTargets and therapy

authors： Wu M,Ye X,Deng X,Wu Y,Li X,Zhang L

更新日期：2016-03-18 00:00:00

abstract：Background:Growth differentiation factor (GDF) acted as a factor that regulated proliferation, apoptosis and differentiation in several tumors. However, the effects of growth differentiation factor (GDF11) in pancreatic cancer remain unclear. Purpose:To investigate the expression and significance of GDF11 in pancreati...

journal_title：OncoTargets and therapy

authors： Liu Y,Shao L,Chen K,Wang Z,Wang J,Jing W,Hu M

更新日期：2018-11-27 00:00:00

abstract：:Malignant gliomas are invasive tumors with the potential to progress through current available therapies. These tumors are characterized by a number of abnormalities in molecular signaling that play roles in tumorigenesis, spread, and survival. These pathways are being actively investigated in both the pre-clinical an...

journal_title：OncoTargets and therapy

authors： Lukas RV,Boire A,Nicholas MK

更新日期：2009-02-18 00:00:00

abstract：Background and objective:Transcriptional coactivator with PDZ-binding motif (TAZ) has been found to be associated with tumor progression. Mitochondrial homeostasis regulates cancer cell viability and metastasis. However, the roles of TAZ and mitochondrial homeostasis in liver cancer viability have not been explored. Th...

journal_title：OncoTargets and therapy

authors： Hou Y,Lan C,Kong Y,Zhu C,Peng W,Huang Z,Zhang C

更新日期：2019-03-01 00:00:00

abstract：Background:New evidence suggests that histidine triad nucleotide-binding protein 1 (Hint1) exerts a tumor suppressor effect in various human tumors, such as colorectal cancer and gastric cancer. However, it has not been reported whether Hint1 is involved in the occurrence and development of osteosarcoma (OS). Material...

journal_title：OncoTargets and therapy

authors： Duan DD,Xie H,Shi HF,Huang WW,Ding F,Hong JK,Fan JS,Hu SY,Wang QW,Zhou MQ

更新日期：2020-08-19 00:00:00

abstract：:Recent studies have shown that microRNAs play a pivotal role in the pathogenesis of cancer. In our current study, the expression levels of microRNA-211 (miR-211) were measured in human non-small-cell lung cancer (NSCLC) tissues and cell lines. We found that miR-211 expression levels were increased in NSCLC tissues and...

journal_title：OncoTargets and therapy

authors： Kang M,Shi J,Peng N,He S

更新日期：2017-11-28 00:00:00

abstract：Background:Several trials evaluated the role of intensive regimens, made of triplet chemotherapies plus bevacizumab, as first-line treatment for patients with metastatic colorectal cancer (mCRC). We previously reported, in a Phase II prospective study, the efficacy and the tolerability of FIrB/FOx regimen, reporting in...

journal_title：OncoTargets and therapy

authors： Cortellini A,Cannita K,Parisi A,Lanfiuti Baldi P,Venditti O,D'Orazio C,Dal Mas A,Calvisi G,Giordano AV,Vicentini V,Vicentini R,Felicioni L,Marchetti A,Buttitta F,Russo A,Ficorella C

更新日期：2019-03-25 00:00:00

abstract：:EGFR pathway is an important therapeutic target in human tumors, including metastatic colorectal cancer (mCRC). The advent of EGFR-targeted monoclonal antibodies panitumumab and cetuximab has generated promise for the treatment of mCRC and has largely improved patients' progression-free survival (PFS) and overall surv...

journal_title：OncoTargets and therapy

authors： Liu J,Hu J,Cheng L,Ren W,Yang M,Liu B,Xie L,Qian X

更新日期：2016-01-27 00:00:00

abstract：:[This corrects the article DOI: 10.2147/OTT.S262089.]. ...

journal_title：OncoTargets and therapy

authors：

更新日期：2020-11-27 00:00:00

abstract：Background:A biosynthetic ginsenoside, 3-O-β-D-glucopyranosyl-12-O-β-D-glucopyranosyl-dammar-24-ene-3β, 12β, 20S-triol (C3C12PPD), showed antitumor activity against many tumor cells in vitro, especially had better anti-lung cancer activity than Rg3 in vitro and in vivo. However, the effects and molecular mechanisms of ...

journal_title：OncoTargets and therapy

authors： Huang LL,Tang M,Du QQ,Liu CX,Yan C,Yang JL,Li Y

更新日期：2019-09-09 00:00:00

abstract：:Acute pancreatitis is a rare complication in postoperative colorectal cancer patients after FOLFOX6 (oxaliplatin + calcium folinate +5-FU [5-fluorouracil]) chemotherapy. In this paper, a total of 62 patients with gastrointestinal cancer were observed after the burst of acute pancreatitis. Surgery of the 62 cases of co...

journal_title：OncoTargets and therapy

authors： Ji Y,Han Z,Shao L,Li Y,Zhao L,Zhao Y

更新日期：2015-09-11 00:00:00

abstract：:Bladder cancer (BC) is the most common urinary system malignancy and is a serious threat to human health. Circular RNAs (circRNAs) are members of a newly defined class of noncoding RNAs (ncRNAs) that can regulate gene expression at the transcriptional or posttranscriptional level. Studies have shown that circRNAs are ...

journal_title：OncoTargets and therapy

authors： Cai Z,Li H

更新日期：2020-09-29 00:00:00

abstract：:Purpose: Numerous microRNAs (miRNAs) are aberrantly expressed in breast cancer, and the dysregulation of miRNAs may affect the aggressiveness of this cancer. Aberrant expression of miRNA-937 (miR-937) in gastric and lung cancers has been reported, which plays tumor-suppressive or oncogenic roles in carcinogenesis incl...

journal_title：OncoTargets and therapy

authors： Han X,Guo X,Zhang W,Cong Q

更新日期：2019-06-20 00:00:00

abstract：Purpose:Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer and its incidence continues to rise yearly. Photodynamic therapy (PDT) is a non-invasive form of cancer therapy, which utilizes the combined action of a photosensitizer, light, and oxygen molecules to selectively cause cellul...

journal_title：OncoTargets and therapy

authors： Shi S,Zheng G,Yang C,Chen X,Yan Q,Jiang F,Jiang X,Xin Y,Jiang G

更新日期：2019-12-31 00:00:00

abstract：BACKGROUND:Several studies have reported an association between the A23G polymorphism (rs 1800975) in the xeroderma pigmentosum group A (XPA) gene and risk of digestive system cancers. However, the results are inconsistent. In this study, we performed a meta-analysis to assess the association between XPA A23G polymorph...

journal_title：OncoTargets and therapy

authors： He L,Deng T,Luo H

更新日期：2015-02-05 00:00:00

abstract：:Glioma is the most common and aggressive human primary tumor in the central nervous system. Despite present clinical advancements, median survival time remains poor in this malignant tumor. Serpin peptidase inhibitor, clade A member 3 (SERPINA3), is a member of the serpin superfamily of protease inhibitors. Its aberra...

journal_title：OncoTargets and therapy

authors： Luo D,Chen W,Tian Y,Li J,Xu X,Chen C,Li F

更新日期：2017-04-18 00:00:00

abstract：:Trastuzumab is a monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2). HER2 is amplified or overexpressed in about 15% of breast cancers and is associated with aggressive disease. Clinical benefits of trastuzumab have been established in the treatment of both early and metastatic HE...

journal_title：OncoTargets and therapy

authors： Hamizi S,Freyer G,Bakrin N,Henin E,Mohtaram A,Le Saux O,Falandry C

更新日期：2013-01-01 00:00:00

abstract：Objective:As an epidermal growth factor, receptor-tyrosine kinase inhibitor (EGFR-TKI), gefitinib demonstrates a good therapeutic effect in patients with EGFR-mutant non-small-cell lung cancer (NSCLC). However, an overwhelming majority of these patients inevitably develop resistance against gefitinib. Unfortunately, th...

journal_title：OncoTargets and therapy

authors： Zhang D,Han LL,Du F,Liu XM,Li J,Wang HH,Song MH,Li Z,Li GY

更新日期：2019-11-18 00:00:00

abstract：:Gastric cancer (GC) is one of the leading causes of tumor-related mortality. In addition to surgery and endoscopic resection, systemic therapy remains the main treatment option for GC, especially for advanced-stage disease and for cases not suitable for surgical therapy. Hence, improving the efficacy of systemic thera...

journal_title：OncoTargets and therapy

authors： Zhao X,Hu GF,Shi YF,Xu W

更新日期：2019-12-24 00:00:00

abstract：Background:Previous studies have reported that nuclear receptor subfamily 5, group A, member 2 (NR5A2) polymorphisms (rs3790843 G>A, rs3790844 T>C, rs12029406 C>T) are associated with the risk of pancreatic cancer. However, the results of epidemiological investigations are still controversial. In order to explore its p...

journal_title：OncoTargets and therapy

authors： Chen Q,Yuan H,Shi GD,Wu Y,Liu DF,Lin YT,Chen L,Ge WL,Jiang K,Miao Y

更新日期：2018-05-09 00:00:00

abstract：BACKGROUND:Nivolumab (BMS-936558/ONO-4538) was the first monoclonal antibody targeting programmed death (PD)-1. So far, a number of clinical trials on nivolumab have showed satisfactory efficacy in treating non-small-cell lung cancer (NSCLC). Herein, we present a meta-analysis evaluating the efficacy and safety of nivo...

journal_title：OncoTargets and therapy

authors： Huang J,Zhang Y,Sheng J,Zhang H,Fang W,Zhan J,Zhou T,Chen Y,Liu L,Zhang L

更新日期：2016-09-23 00:00:00

abstract：AIM:To investigate the clinical significance of cyclic adenosine monophosphate-responsive element-binding (CREB) and phosphorylated CREB (pCREB) expression in human hepatocellular carcinoma (HCC). MATERIALS AND METHODS:Immunohistochemistry and Western blot analyses were performed to detect the expression and subcellul...

journal_title：OncoTargets and therapy

authors： Yu L,Guo X,Zhang P,Qi R,Li Z,Zhang S

更新日期：2014-05-29 00:00:00

abstract：BACKGROUND:Repetitive genotyping is useful to assess the genetic evolution of non-small-cell lung cancer (NSCLC) during treatment, but the need for sampling by biopsy is a major obstacle. Digital polymerase chain reaction (PCR) is a promising procedure for the detection of mutant alleles in plasma of cancer patients. ...

journal_title：OncoTargets and therapy

authors： Nakahara Y,Takagi Y,Hosomi Y,Kagei A,Yamamoto T,Sawada T,Yomota M,Okuma Y,Mikura S,Okamura T

更新日期：2016-08-24 00:00:00

abstract：Background:Anti-programmed cell death-1/programmed cell death ligand-1 monoclonal antibodies have been widely used in non-small-cell lung cancer (NSCLC), but not every patient can get benefits from them. Whether other molecular markers can predict the results of programmed cell death-1/programmed cell death ligand-1 in...

journal_title：OncoTargets and therapy

authors： He Y,Wang Y,Zhao S,Zhao C,Zhou C,Hirsch FR

更新日期：2018-08-13 00:00:00

abstract：PURPOSE:Programmed death-ligand 1 (PD-L1) is found to be overexpressed in non-small cell lung cancer. The present study intended to evaluate the status of PD-L1 expression in patients with resection and recurrent lung adenocarcinoma. PATIENTS AND METHODS:Matched resection and recurrent tumor samples were harvested fro...

journal_title：OncoTargets and therapy

authors： Chen J,Li H,Pang R,Huang J

更新日期：2017-04-06 00:00:00

abstract：BACKGROUND:Two types of epidermal growth factor receptor (EGFR) mutations in exon 19 and exon 21 (ex19del and L858R) are prevalent in lung cancer patients and sensitive to targeted EGFR inhibition. A resistance mutation in exon 20 (T790M) has been found to accompany drug treatment when patients relapse. These three mut...

journal_title：OncoTargets and therapy

authors： Xu Q,Zhu Y,Bai Y,Wei X,Zheng X,Mao M,Zheng G

更新日期：2015-06-22 00:00:00

abstract：:Cancers of the stomach and gastro-esophageal junction represent a significant challenge in oncology. Despite some recent advances in genetic categorization and the development of novel agents, outcomes remain poor. The vascular endothelial growth factor receptor 2 monoclonal antibody ramucirumab is the first targeted ...

journal_title：OncoTargets and therapy

authors： Davidson M,Smyth EC,Cunningham D

更新日期：2016-07-25 00:00:00

abstract：AIM:To investigate the significance of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER)2, and HER3 expression on survival outcomes in Chinese gastric cancer patients. MATERIALS AND METHODS:Formalin-fixed, paraffin-embedded specimens from 121 patients who underwent gastrectomy at Sh...

journal_title：OncoTargets and therapy

authors： Tang D,Liu CY,Shen D,Fan S,Su X,Ye P,Gavine PR,Yin X

更新日期：2014-12-16 00:00:00